NBIX - Neurocrine Biosciences Inc Stock Price, Fair Value and News

141.87USD-1.32 (-0.92%)Market Closed as of 08 May 2024, 09:50 am ET

Market Summary

USD141.87-1.32

Market Closedas of 08 May 2024, 09:50 am

-0.92%

NBIX Alerts

1 major insider sales recently.

Big jump in Earnings (Y/Y)

NBIX Stock Price

View Fullscreen

NBIX RSI Chart

NBIX Valuation

Market Cap

14.4B

Price/Earnings (Trailing)

38.97

Price/Sales (Trailing)

7.27

EV/EBITDA

28.45

Price/Free Cashflow

23.45

NBIX Price/Sales (Trailing)

NBIX Profitability

Operating Margin

99.28%

EBT Margin

23.71%

Return on Equity

15.49%

Return on Assets

10.65%

Free Cashflow Yield

4.26%

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

22.57%

Rev. Growth (Qtr)

0.02%

NBIX Earnings

Earnings (TTM)

369.7M

Earnings Growth (Yr)

156.66%

Earnings Growth (Qtr)

-70.62%

Breaking Down NBIX Revenue

52 Week Range

89.04143.44

(Low)(High)

Last 7 days

4.1%

Last 30 days

3.1%

Last 90 days

5.1%

Trailing 12 Months

46.2%

How does NBIX drawdown profile look like?

NBIX Financial Health

Current Ratio

2.52

Debt/Equity

0.07

Debt/Cashflow

3.81

NBIX Investor Care

Shares Dilution (1Y)

3.14%

Diluted EPS (TTM)

3.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0B	0	0	0
2023	1.6B	1.7B	1.8B	1.9B
2022	1.2B	1.3B	1.4B	1.5B
2021	1.0B	1.0B	1.1B	1.1B
2020	886.8M	1.0B	1.0B	1.0B
2019	518.6M	605.1M	675.5M	788.1M
2018	232.7M	323.3M	414.3M	451.2M
2017	0	6.3M	67.1M	161.6M
2016	15.0M	15.0M	15.0M	15.0M
2015	22.0M	21.2M	20.5M	19.8M
2013	40.6M	28.0M	15.5M	2.9M
2012	76.2M	74.6M	42.3M	53.1M
2011	45.3M	52.8M	80.0M	77.4M
2010	0	13.1M	23.3M	33.5M
2009	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Neurocrine Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	benevich eric	sold	-2,643,020	133	-19,818	chief commercial officer
Apr 15, 2024	benevich eric	acquired	1,609,430	81.2105	19,818	chief commercial officer
Apr 01, 2024	delaet ingrid	sold	-37,345	137	-272	chief regulatory officer
Apr 01, 2024	delaet ingrid	acquired	21,493	79.02	272	chief regulatory officer
Mar 21, 2024	delaet ingrid	acquired	517,600	103	5,000	chief regulatory officer
Mar 21, 2024	delaet ingrid	sold	-725,320	145	-5,000	chief regulatory officer
Mar 14, 2024	morrow george j	sold	-5,576,710	139	-40,000	-
Mar 14, 2024	morrow george j	acquired	795,800	39.79	20,000	-
Mar 14, 2024	benevich eric	sold	-10,453,400	139	-75,000	chief commercial officer
Mar 14, 2024	benevich eric	acquired	6,067,630	80.9017	75,000	chief commercial officer

Which funds bought or sold NBIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	DiNuzzo Private Wealth, Inc.	unchanged	-	31.00	690	-%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-1,055	-	-%
May 06, 2024	LMCG INVESTMENTS, LLC	reduced	-27.85	-303,970	938,132	0.06%
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	reduced	-2.18	72,000	3,081,000	0.02%
May 06, 2024	Quantbot Technologies LP	reduced	-98.46	-219,220	3,586	-%
May 06, 2024	HighTower Advisors, LLC	added	3.61	185,000	2,212,000	-%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	reduced	-2.4	31,925	1,505,400	0.01%
May 06, 2024	Savant Capital, LLC	new	-	2,150,590	2,150,590	0.03%
May 06, 2024	Manchester Capital Management LLC	new	-	414	414	-%
May 06, 2024	Envestnet Portfolio Solutions, Inc.	added	0.47	17,240	350,593	-%

Are Funds Buying or Selling NBIX?

Are funds buying NBIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NBIX

No. of Funds

Unveiling Neurocrine Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.88%	9,710,328	SC 13G/A
Jan 23, 2024	blackrock inc.	13.9%	13,647,679	SC 13G/A
Feb 09, 2023	janus henderson group plc	2.5%	2,415,638	SC 13G/A
Feb 09, 2023	vanguard group inc	9.72%	9,340,295	SC 13G/A
Jan 23, 2023	blackrock inc.	13.1%	12,627,403	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	4.5%	4,359,645	SC 13G/A
Feb 10, 2022	vanguard group inc	9.26%	8,787,991	SC 13G/A
Feb 10, 2022	janus henderson group plc	7.8%	7,445,839	SC 13G/A
Jan 27, 2022	blackrock inc.	12.1%	11,476,545	SC 13G/A
Jan 26, 2022	blackrock inc.	12.1%	11,476,545	SC 13G/A

Recent SEC filings of Neurocrine Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 21, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Neurocrine Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.6B	-2.43%	-8.39%	9.3	4.18	5.68%	202.39%
MRK	330.2B	61.4B	1.86%	10.13%	143.19	5.38	6.11%	-82.30%
AMGN	161.1B	29.5B	11.28%	28.04%	42.82	5.46	12.76%	-52.47%
PFE	156.8B	46.5B	4.16%	-28.19%	-112.94	3.37	42.59%	-114.62%
GILD	81.5B	27.1B	-5.96%	-16.75%	14.39	3.01	-0.60%	23.36%
TEVA	15.6B	15.8B	-2.04%	54.08%	-27.14	0.99	6.17%	76.47%
MID-CAP
ALKS	4.2B	1.7B	-5.86%	-20.45%	9.58	2.41	54.01%	364.56%
PRGO	4.1B	4.6B	-3.95%	-16.22%	-533.77	0.9	-0.06%	94.55%
BHC	2.7B	9.0B	-28.82%	23.71%	-5.97	0.3	10.01%	-27.45%
AMPH	2.1B	644.4M	2.42%	17.52%	14.96	3.19	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-23.46%	-28.42%	-4.38	2.07	24.65%	80.36%
TXMD	23.2M	1.3M	-9.05%	-48.20%	-2.26	17.8	-98.14%	-109.18%
ACRX	17.0M	-	-15.25%	35.14%	-0.92	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	31.03%	-94.02%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Neurocrine Biosciences Inc News

Latest updates

Neurocrine Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	0.0%	515	515	499	453	420	412	388	378	311	312	296	289	237	248	259	302	237	244	222	184	138
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	-	1.00
Costs and Expenses	14.0%	416	365	358	379	535	309	300	324	308	348	252	226	205	176	303	226	178	-	132	149	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	326	-	-	-	176	303	226	178	195	132	149	239
S&GA Expenses	11.1%	243	219	204	222	243	183	186	183	201	157	155	143	129	107	113	97.00	118	101	85.00	81.00	88.00
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	73.00	-	-	-	58.00	-	-	62.00	38.00
EBITDA Margin	32.2%	0.25*	0.19*	0.15*	0.15*	0.07*	0.16*	0.08*	0.04*	0.11*	0.12*	0.18*	0.10*	-	-	-	-	-	-	-	-	-
Interest Expenses	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	3.00	7.00	7.00	6.00	6.00	8.00	9.00	8.00	8.00	8.00	8.00	8.00	8.00
Income Taxes	-117.6%	-8.90	51.00	33.00	26.00	-26.70	29.00	29.00	-6.40	8.00	-6.50	8.00	15.00	-4.90	-306	1.00	4.00	2.00	5.00	5.00	1.00	-0.50
Earnings Before Taxes	-82.6%	35.00	198	116	122	-103	118	98.00	-23.30	21.00	-13.80	31.00	58.00	27.00	42.00	-57.10	83.00	39.00	39.00	58.00	52.00	-102
EBT Margin	34.7%	0.24*	0.18*	0.14*	0.14*	0.06*	0.14*	0.06*	0.01*	0.08*	0.09*	0.15*	0.07*	-	-	-	-	-	-	-	-	-
Net Income	-70.6%	43.00	148	83.00	96.00	-76.60	89.00	69.00	-16.90	14.00	-7.30	23.00	42.00	32.00	348	-57.60	80.00	37.00	34.00	54.00	51.00	-102
Net Income Margin	41.0%	0.19*	0.13*	0.11*	0.11*	0.04*	0.10*	0.04*	0.01*	0.06*	0.08*	0.42*	0.35*	-	-	-	-	-	-	-	-	-
Free Cashflow	0.8%	119	118	204	173	-133	141	101	129	-48.10	-4.70	56.00	99.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	6.8%	3,472	3,251	2,848	2,613	2,360	2,369	2,143	2,006	2,145	2,073	2,017	1,956	1,846	1,735	1,503	1,516	1,362	1,306	1,180	1,067	958
Current Assets	11.9%	1,799	1,607	1,650	1,497	1,433	1,454	1,206	1,019	1,018	973	1,006	1,110	1,085	1,016	1,157	1,146	968	831	819	749	633
Cash Equivalents	61.0%	404	251	294	160	104	263	212	163	270	344	311	368	353	190	425	415	187	116	172	147	78.00
Inventory	-2.9%	37.00	38.00	29.00	32.00	33.00	35.00	37.00	29.00	29.00	31.00	26.00	28.00	30.00	28.00	21.00	22.00	21.00	17.00	11.00	12.00	13.00
Net PPE	6.4%	75.00	71.00	69.00	66.00	63.00	59.00	61.00	67.00	64.00	59.00	51.00	50.00	45.00	45.00	43.00	45.00	42.00	42.00	40.00	40.00	37.00
Liabilities	6.6%	1,086	1,019	846	760	675	661	599	582	753	699	671	677	641	609	698	684	662	669	605	583	548
Current Liabilities	8.9%	713	655	692	583	374	538	485	286	254	246	226	213	190	187	611	573	140	565	116	101	72.00
Long Term Debt	-	-	-	-	-	170	-	-	169	378	335	331	326	322	318	-	-	414	-	404	398	393
LT Debt, Current	-27.8%	123	170	170	170	-	169	169	-	-	-	-	-	-	-	425	420	-	409	-	-	-
LT Debt, Non Current	-	-	-	-	-	170	-	-	169	378	335	331	326	322	318	-	-	414	-	404	398	393
Shareholder's Equity	6.9%	2,386	2,232	2,002	1,853	1,685	1,708	1,545	1,423	1,391	1,374	1,346	1,279	1,206	1,126	804	831	700	637	575	484	409
Retained Earnings	27.6%	-113	-157	-304	-387	-483	-406	-495	-564	-547	-635	-628	-651	-693	-725	-1,073	-1,015	-1,095	-1,132	-1,166	-1,220	-1,271
Additional Paid-In Capital	4.8%	2,496	2,382	2,309	2,242	2,171	2,122	2,054	2,000	1,948	2,011	1,974	1,929	1,898	1,850	1,874	1,842	1,797	1,768	1,740	1,703	1,681
Shares Outstanding	1.9%	101	99.00	98.00	98.00	98.00	97.00	96.00	95.00	95.00	95.00	95.00	94.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	7,900	-	-	-	8,097	-	-	-	9,105	-	-	-	11,232	-	-	-	5,753	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	5.5%	130,300	123,500	212,000	179,600	-125,200	143,000	98,800	138,100	-40,500	4,200	61,800	103,200	87,300	94,500	-20,400	118,900	35,500	97,500	97,800	64,200	-112,500
Share Based Compensation	16.8%	44,500	38,100	47,800	68,500	39,900	43,500	43,100	49,500	37,000	35,600	37,100	28,600	32,900	21,000	26,700	29,500	22,800	21,300	20,300	17,900	15,800
Cashflow From Investing	72.7%	-55,000	-201,800	-97,300	-125,900	-42,100	-115,600	-61,300	31,400	-31,600	23,700	-126,200	-90,800	63,100	-147,700	25,200	93,400	33,200	-166,200	-85,600	-300	41,000
Cashflow From Financing	97.5%	69,900	35,400	18,800	2,900	8,200	24,600	11,400	-276,400	6,100	1,800	7,500	3,000	15,100	-185,000	5,400	15,800	6,000	12,400	13,100	4,300	2,600

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NBIX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 515.3	$ 420.4
Operating expenses:
Cost of revenues	7.5	8.5
Research and development	159.4	139.5
Acquired in-process research and development	6.0	143.9
Selling, general and administrative	243.1	242.7
Total operating expenses	416.0	534.6
Operating income (loss)	99.3	(114.2)
Other (expense) income:
Interest expense	(1.1)	(1.1)
Unrealized gain on equity security investments	1.6	2.2
Charges associated with convertible senior notes	(88.7)	0.0
Investment income and other, net	23.4	9.8
Total other (expense) income, net	(64.8)	10.9
Income (loss) before benefit from income taxes	34.5	(103.3)
Benefit from income taxes	(8.9)	(26.7)
Net income (loss)	43.4	(76.6)
Foreign currency translation adjustments, net of tax	(0.5)	1.2
Unrealized (loss) gain on debt securities available-for-sale, net of tax	(3.2)	4.0
Comprehensive income (loss)	$ 39.7	$ (71.4)
Earnings (loss) per share:
Basic (in USD per share)	$ 0.43	$ (0.79)
Diluted (in USD per share)	$ 0.42	$ (0.79)
Weighted-average shares outstanding:
Basic (in shares)	99.8	97.1
Diluted (in shares)	103.6	97.1
Net product sales
Revenues:
Total revenues	$ 509.0	$ 415.3
Collaboration revenues
Revenues:
Total revenues	$ 6.3	$ 5.1

NBIX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 396.3	$ 251.1
Debt securities available-for-sale	814.3	780.5
Accounts receivable	450.7	439.3
Inventory	37.2	38.3
Other current assets	100.5	97.8
Total current assets	1,799.0	1,607.0
Deferred tax assets	378.2	362.6
Debt securities available-for-sale	700.4	687.5
Right-of-use assets	270.8	276.5
Equity security investments	163.5	161.9
Property and equipment, net	75.3	70.8
Intangible assets, net	34.3	35.5
Other noncurrent assets	50.9	49.6
Total assets	3,472.4	3,251.4
Current liabilities:
Accounts payable and accrued liabilities	417.2	448.8
Convertible senior notes, at carrying value ($170.4 face value as of March 31, 2024 and December 31, 2023)	122.8	170.1
Convertible senior notes embedded derivative liability	136.2	0.0
Other current liabilities	36.7	35.9
Total current liabilities	712.9	654.8
Noncurrent operating lease liabilities	252.9	258.3
Other noncurrent liabilities	120.5	106.3
Total liabilities	1,086.3	1,019.4
Stockholders’ equity:
Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding	0.0	0.0
Common stock, $0.001 par value; 220.0 shares authorized; 100.6 and 98.7 shares issued and outstanding, respectively	0.1	0.1
Additional paid-in capital	2,496.4	2,382.0
Accumulated other comprehensive income	3.3	7.0
Accumulated deficit	(113.7)	(157.1)
Total stockholders’ equity	2,386.1	2,232.0
Total liabilities and stockholders’ equity	$ 3,472.4	$ 3,251.4

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Ã‚â€“ Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

CEO	Dr. Kevin C. Gorman Ph.D.
WEBSITE	neurocrine.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	1350

Neurocrine Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Neurocrine Biosciences Inc? What does NBIX stand for in stocks?

NBIX is the stock ticker symbol of Neurocrine Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neurocrine Biosciences Inc (NBIX)?

As of Tue May 07 2024, market cap of Neurocrine Biosciences Inc is 14.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers. The fair value of Neurocrine Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neurocrine Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neurocrine Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether NBIX is over valued or under valued. Whether Neurocrine Biosciences Inc is cheap or expensive depends on the assumptions which impact Neurocrine Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBIX.

What is Neurocrine Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, NBIX's PE ratio (Price to Earnings) is 38.97 and Price to Sales (PS) ratio is 7.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Neurocrine Biosciences Inc's stock?

In the past 10 years, Neurocrine Biosciences Inc has provided 0.263 (multiply by 100 for percentage) rate of return.